Stearacl

Steara Therapeutics is a clinical-stage biotechnology company focused on developing innovative topical treatments for dermatological conditions. The company's lead candidate, ST-011, is a potent and selective small molecule inhibitor of stearoyl-CoA desaturase 1 (SCD1), designed to reduce sebum production at the source. By targeting the rate-limiting enzyme in the synthesis of monounsaturated fatty acids, Steara aims to provide a novel mechanism of action for treating acne and seborrheic dermatitis. The company is currently advancing its pipeline through clinical trials to address significant unmet needs in the dermatology market.